Ipca Laboratories (NSE:IPCALAB) EPS without NRI: ₹46.94 (TTM As of Mar. 2026)


NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
91 GF Score
Price ₹1,770.40
GF Value ₹1,601.33
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Ipca Laboratories EPS without NRI?

Ipca Laboratories NSE:IPCALAB -1.71% 91 EPS without NRI is ₹46.94 as of Mar. 2026. GuruFocus rates NSE:IPCALAB with a GF Score™ of 91/100 and a GF Value™ of ₹1,601.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, Ipca Laboratories ranks better than 81.42% on this metric.

Ipca Laboratories's earnings per share without non-recurring items for the three months ended in Mar. 2026 was ₹13.31. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹46.94.

During the past 12 months, Ipca Laboratories's average earnings per share (NRI) Growth Rate was 35.20% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 36.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 1.50% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 22.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Ipca Laboratories's EPS without NRI or its related term are showing as below:

NSE:IPCALAB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34.3   Med: 18.4   Max: 69.2
Current: 36.2

During the past 13 years, Ipca Laboratories's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 69.20% per year. The lowest was -34.30% per year. And the median was 18.40% per year.

NSE:IPCALAB's 3-Year EPS without NRI Growth Rate is ranked better than
81.42% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.6 vs NSE:IPCALAB: 36.20

Ipca Laboratories's EPS (Diluted) for the three months ended in Mar. 2026 was ₹11.79. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹44.98.

Ipca Laboratories's EPS (Basic) for the three months ended in Mar. 2026 was ₹11.79. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹44.98.


Ipca Laboratories  (NSE:IPCALAB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ipca Laboratories EPS without NRI Related Terms


Ipca Laboratories EPS without NRI Historical Data

* Premium members only.

The historical data trend for Ipca Laboratories's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories EPS without NRI Chart

Ipca Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.73 18.58 25.82 34.71 46.94

Ipca Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.32 9.19 12.35 12.09 13.31

NSE:IPCALAB vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's PE Ratio without NRI falls into.


NSE:IPCALAB
91GF Score
Ipca Laboratories Ltd NSE:IPCALAB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipca Laboratories EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹46.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of ₹46.94 mean?
Ipca Laboratories (NSE:IPCALAB) has a EPS without NRI of ₹46.94 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ipca Laboratories and its competitors. According to the industry distribution chart, Ipca Laboratories ranks #146 out of 786 companies in the Drug Manufacturers industry, placing it in the top 18.6%.
Is Ipca Laboratories' EPS without NRI too high?
Ipca Laboratories' current EPS without NRI is ₹46.94. Based on the distribution chart, Ipca Laboratories ranks #146 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ipca Laboratories has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #146 out of 786 companies for EPS without NRI. This places Ipca Laboratories in the top 19% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current EPS without NRI is ₹46.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,601.33, compared to a current price of ₹1,770.40 — trading 10.6% above its estimated fair value. The current EPS without NRI is ₹46.94. Ipca Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current EPS without NRI is ₹46.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,770.40 is trading 10.6% above its estimated GF Value™ of ₹1,601.33. GuruFocus considers Ipca Laboratories to be Fairly Valued.

Key valuation signals for NSE:IPCALAB:

  • EPS without NRI: ₹46.94
  • GF Value™: ₹1,601.33 vs. price of ₹1,770.40 (10.6% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
91GF Score

Get the complete analysis for NSE:IPCALAB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,770.40
Price
₹1,601.33
GF Value